SCHEMBL3425952

SCHEMBL3425952

CSC1=NC(=O)C(=Cc2ccc(F)cc2O)S1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.51
ALDH1A1 P00352 4/20 0.51
KMT2A Q03164 4/20 0.51
POLB P06746 3/20 0.51
GLA P06280 1/20 0.51
HTT P42858 1/20 0.51
GAA P10253 2/20 0.50
PTGS1 P23219 1/20 0.50
PTGS2 P35354 1/20 0.50
MYC P01106 1/20 0.47
MAX P61244 1/20 0.47
CHEK1 O14757 1/20 0.46
DAPK3 O43293 1/20 0.46
PRKD3 O94806 1/20 0.46
PIM1 P11309 1/20 0.46
MAPK8 P45983 1/20 0.46
CSNK1A1 P48729 1/20 0.46
CDK8 P49336 1/20 0.46
CLK2 P49760 1/20 0.46
CDK9 P50750 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3425948 1.00 MAPT (0.51) MAPTALDH1A1KMT2APOLBGLA
SCHEMBL4349225 0.90 KMT2A (0.51) MAPTALDH1A1KMT2APOLBGLA
SCHEMBL3400659 0.90 KMT2A (0.51) MAPTALDH1A1KMT2APOLBGLA
SCHEMBL3400663 0.90 KMT2A (0.51) MAPTALDH1A1KMT2APOLBGLA
SCHEMBL13616175 0.81 CHEK1 (0.44) MAPTALDH1A1KMT2APOLBGAA
SCHEMBL3404378 0.80 PTGS1 (0.48) MAPTALDH1A1KMT2APOLBGLA
SCHEMBL3404375 0.80 PTGS1 (0.48) MAPTALDH1A1KMT2APOLBGLA
SCHEMBL3431054 0.78 KMT2A (0.50) MAPTALDH1A1KMT2APOLBGLA
SCHEMBL3431049 0.78 KMT2A (0.50) MAPTALDH1A1KMT2APOLBGLA
SCHEMBL3427925 0.75 RAB9A (0.62) MAPTALDH1A1KMT2APOLBHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2250167-A1 ARYLMETHYLIDENE HETEROCYCLES AS NOVEL ANALGESICS Chlorion Pharma, Inc. (CA) 2010-11-17 EP disclosed
US-20090275538-A1 ARYLMETHYLIDENE HETEROCYCLES AS NOVEL ANALGESICS UNIVERSITE LAVAL (CA) 2009-11-05 US disclosed
US-20090275538-A1 ARYLMETHYLIDENE HETEROCYCLES AS NOVEL ANALGESICS UNIVERSITE LAVAL (CA) 2009-11-05 US disclosed
US-20090275538-A1 ARYLMETHYLIDENE HETEROCYCLES AS NOVEL ANALGESICS UNIVERSITE LAVAL (CA) 2009-11-05 US disclosed
WO-2009097695-A1 ARYLMETHYLIDENE HETEROCYCLES AS NOVEL ANALGESICS CHLORION PHARMA, INC. (CA) 2009-08-13 WO disclosed
WO-2009097695-A1 ARYLMETHYLIDENE HETEROCYCLES AS NOVEL ANALGESICS CHLORION PHARMA, INC. (CA) 2009-08-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275538-A1 ARYLMETHYLIDENE HETEROCYCLES AS NOVEL ANALGESICS OPRL1, OPRK1, AHR MAPT 3804/4885ALDH1A1 211/4885KMT2A 1752/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.